bioecon Member area
Technology · Health & biomedicine / Regenerative & personalized medicine

Biomimetic medical adhesives

Bio-inspired surgical adhesives, sealants and hemostatic gels that bond, seal or stop bleeding in wet tissue environments where conventional sutures and staples struggle — drawing on biological adhesion mechanisms such as mussel/oyster adhesive proteins: Tissium in France, Cresilon and Brij Medical in the US, and Adhesys Medical in Germany.

Maturity 5/9 Risk: medium Medical devices & implants US · EU · CN Science: why it works → verified 2026-07-20 · 4 Sources (0 independent)

1 · What it gives

Biomimetic medical adhesives bond, seal or stop bleeding in wet, moving tissue environments where conventional sutures and staples are slow, traumatic or ineffective, drawing on biological adhesion mechanisms — such as the proteins mussels and oysters use to bond to wet rock — to work where synthetic glues typically fail. Tissium’s bioinspired polymer platform recently published first-in-human clinical results for its Coaptium Connect system, an atraumatic sutureless nerve-repair device, and the company secured EUR 60 million to support commercial and clinical activities and platform expansion, following an earlier EUR 30 million equity plus EUR 30 million debt raise. Cresilon’s biomimetic hemostatic gel technology, marketed as TraumaGel, showed promising results for treating penetrating traumatic brain injury in a study with the Walter Reed Army Institute of Research, received an Innovative Technology contract from Vizient, and was named to Fast Company’s Most Innovative Companies list for 2026. Brij Medical launched Brij-Seal, expanding its incision-management portfolio with an advanced wound sealant engineered for strength, flexibility and biocompatibility, alongside its BRIJJIT product line securing an ECAT government-procurement listing. In Germany, Adhesys Medical develops polyurethane-based surgical adhesive and sealant technology.

The key directions of biomimetic medical adhesives are:

  1. Bioinspired sutureless tissue repair (Bioinspired Sutureless Repair): biomimetic polymer platforms replacing sutures for nerve and soft-tissue repair, validated in first-in-human clinical studies — Tissium’s Coaptium Connect.
  2. Biomimetic hemostatic gel technology (Biomimetic Hemostatic Gel): rapid-acting hemostatic gels inspired by biological adhesion chemistry, validated for trauma and penetrating-injury bleeding control — Cresilon’s TraumaGel.
  3. Advanced wound sealants (Advanced Wound Sealants): incision-management sealants engineered for strength, flexibility and biocompatibility as an adjunct or alternative to sutures — Brij Medical’s Brij-Seal.
  4. Polyurethane-based surgical adhesives (Polyurethane Surgical Adhesives): synthetic polyurethane adhesive chemistry adapted for surgical tissue bonding — Adhesys Medical.

Sectoral value chain#

[bioinspired adhesive chemistry design] ──> [preclinical/clinical validation] ──> [regulatory clearance (FDA/MDR)]
                                                    │
                                       (surgical/trauma deployment)
                                                    │
                                                    ▼
[label expansion to new indications] <─── [clinical outcome data generation] <─────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Adhesive Chemistry Designengineering a polymer or gel chemistry that bonds, seals or clots in a wet, dynamic tissue environmentIn: biological adhesion mechanism (mussel/oyster protein analog), polymer chemistry.
Out: biomimetic adhesive formulation.
Preclinical/Clinical Validationtesting adhesion strength, biocompatibility and hemostatic/sealing performance in animal and human studiesIn: adhesive formulation, study protocol.
Out: clinical performance data.
Regulatory ClearanceFDA 510(k)/PMA or EU MDR conformity assessment of the device’s specific surgical claimIn: clinical validation data.
Out: cleared/CE-marked device.
Surgical/Trauma Deploymentthe adhesive, sealant or hemostatic gel is used in the operating room or trauma/field settingIn: cleared product.
Out: applied surgical/trauma product.
Clinical Outcome Datareal-world and study data on bleeding control, healing and complication rates are collectedIn: deployment cases.
Out: outcome evidence.
Label Expansionoutcome evidence supports expanding the approved indication to new surgical or trauma use casesIn: outcome evidence.
Out: expanded regulatory indication.

Cross-cutting technologies of the sector:

  • Biomimetic adhesion chemistry (Bioinspired Sutureless Repair): polymer chemistries that replicate the wet-surface bonding mechanisms biological organisms (mussels, oysters) use, enabling adhesion where conventional synthetic glues fail on moist tissue.
  • Rapid hemostatic gelation (Biomimetic Hemostatic Gel): gel formulations that rapidly clot or seal a bleeding wound on contact, validated for trauma and penetrating-injury control.
  • Engineered sealant mechanics (Advanced Wound Sealants): formulations balancing strength, flexibility and biocompatibility to function as a sutureless or suture-adjunct incision seal.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 6 steps

  1. 1
    Adhesive chemistry design
    A polymer or gel chemistry is engineered to replicate a biological adhesion mechanism — such as mussel- or oyster-inspired wet-surface bonding — for a specific surgical or trauma bonding, sealing or hemostatic function.
  2. 2
    Preclinical and clinical validationTesting & analytics
    The formulation is tested for adhesion strength, biocompatibility and functional performance (nerve repair, hemorrhage control, incision sealing) in animal studies and, as Tissium and Cresilon have both achieved, human clinical studies.
    Who can do this step matched automatically
    industrial scale
    “The main specialization is assay and analytical laboratory.”
  3. 3
    Regulatory clearanceRegulatory & certification
    The device clears FDA 510(k)/PMA review or EU MDR conformity assessment for its specific surgical indication, with Tissium’s first-in-human nerve-repair data and Cresilon’s trauma studies both supporting this stage.
    Registration in Russia / EAEU: Regulation
  4. 4
    Surgical and trauma deployment
    The cleared adhesive, sealant or hemostatic gel is used in the operating room (Tissium, Adhesys Medical) or trauma/field setting (Cresilon), replacing or supplementing sutures and staples where they underperform.
  5. 5
    Clinical outcome data generation
    Real-world and study data on bleeding control, healing and complication rates are collected, the evidence base behind Cresilon’s Walter Reed-validated trauma results and Vizient contract.
  6. 6
    Label expansionFermentation & cultivation
    Outcome evidence supports expanding the approved indication to new surgical or trauma use cases, the pattern behind Brij Medical’s expansion from its initial BRIJJIT product into the broader Brij-Seal incision-management line.
    Who can do this step matched automatically
    Spiber Japan
    ✓ ISO 9001 industrial scale
    “By harnessing the power of precision fermentation, Spiber engineers proteins at the molecular level, resulting in versatile materials that can be tailored to specific needs.”
    RWDC Industries Singapore
    industrial scale
    “Using a proprietary microbial fermentation process, we produce PHA (polyhydroxyalkanoate), a naturally occurring biopolymer made from plant-based oils.”
    Absolute India
    industrial scale
    “Uses precision fermentation and proprietary gene-editing tools to deliver diabetes-friendly nutrition for 600 million+ people.”
    Pensées South Korea
    pilot scale
    “We have developed a high-efficiency bioreactor specifically for cultured meat production and have secured safety and cost-effectiveness by developing a medium using food-grade …”
    Loopworm India
    6,000 tonnes/year industrial scale
    “At Loopworm, we are building the future of sustainable biomanufacturing.”
    Cell AgriTech Malaysia
    5,000 L industrial scale
    “We design and fabricate our own stainless-steel bioreactors, automation systems, and harvesting modules, which lower CAPEX and OPEX by more than 80% compared to pharma-grade …”

4 · Who delivers

Matched suppliers (matched automatically)

PTT Global Chemical (GC)ThailandResearch / RTOactive
Kyowa Hakko Bio (Kirin)JapanProduceractive
Jiangsu Jland BiotechChinaProduceractive
Jiangsu TrautecChinaProduceractive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Tissium🇫🇷 FranceCoaptium Connect sutureless nerve repairBioinspired polymer, EUR 60M raisedgrowth
Cresilon🇺🇸 USATraumaGel hemostatic gelTrauma/TBI bleeding control, Fast Company 2026growth
Brij Medical🇺🇸 USABrij-Seal / BRIJJITAdvanced wound sealant, ECAT listinggrowth
Adhesys Medical🇩🇪 GermanyPolyurethane surgical adhesiveTissue-bonding chemistrygrowth

5 · Rules & route to market

United States

The US hosts leading biomimetic adhesive and hemostatic gel companies, with real-world trauma and defense-research validation data.

Cresilon, Brij Medical, FDA#

  • Cresilon: its biomimetic hemostatic gel, marketed as TraumaGel, showed promising results for treating penetrating traumatic brain injury in a study with the Walter Reed Army Institute of Research, received an Innovative Technology contract from Vizient, and was named to Fast Company’s Most Innovative Companies list for 2026.
  • Brij Medical: launched Brij-Seal, expanding its incision-management portfolio with an advanced wound sealant engineered for strength, flexibility and biocompatibility, alongside its BRIJJIT product line securing an ECAT government-procurement listing.
  • FDA framework: biomimetic adhesives, sealants and hemostatic gels clear the FDA via 510(k) or PMA review as surgical devices, with each specific indication (nerve repair, hemorrhage control, incision sealing) requiring its own clinical-validation evidence.

European Union

France and Germany anchor Europe’s biomimetic adhesive capacity, spanning a well-funded sutureless-repair platform and polyurethane-based surgical adhesive chemistry.

Tissium, Adhesys Medical, MDR#

  • Tissium (Paris, France): its bioinspired polymer platform recently published first-in-human clinical results for its Coaptium Connect atraumatic sutureless nerve-repair system, and secured EUR 60 million to support commercial and clinical activities and platform expansion, following an earlier EUR 30 million equity plus EUR 30 million debt raise.
  • Adhesys Medical (Germany): develops polyurethane-based surgical adhesive and sealant technology for tissue bonding applications.
  • MDR framework: biomimetic surgical adhesives sold in the EU require conformity assessment under the Medical Device Regulation (MDR 2017/745), with Tissium’s first-in-human data supporting its path through that framework.

China

No dedicated Chinese biomimetic medical adhesive company cleared source confirmation as of 2026; Chinese sources covering this period center on the broader tissue-sealant and medical-adhesive market rather than a specific biomimetic commercial originator.

market coverage, NMPA pathway#

  • Market coverage focus: Chinese industry reporting on tissue sealants and medical adhesives in this period addresses the broader product category rather than a dedicated biomimetic-adhesive platform company.
  • NMPA pathway: any biomimetic surgical adhesive reaching Chinese clinical use would register with NMPA as a medical device, following a validation-heavy pathway given the surgical-use risk classification.

6 · Money: tenders & grants

GrantDoW Joint Warfighter Medical, Military Medical Research and Development Award
Defense Health Agency Contracting Activity - DHACA · United States
Nov 16, 2026
31 days
GrantDOD Defense Health Agency (DHA) Research & Development FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural …
Defense Health Agency Contracting Activity - DHACA · United States
Sep 30, 2027
349 days
GrantIncreasing the resilience of agriculture in water and nutrient-scarce environments through digital innovations
European Commission · EU
Sep 23, 2027
342 days

7 · Tech stack & innovations

The stack applies biologically inspired adhesion and gelation chemistry to bond, seal or stop bleeding in wet tissue environments where conventional sutures, staples and synthetic glues typically underperform.

  1. Bioinspired sutureless repair polymers (Bioinspired Sutureless Repair):
    • Tissium’s biomimetic polymer platform, validated in first-in-human clinical results for its Coaptium Connect system, replaces sutures for atraumatic nerve repair.
  2. Rapid biomimetic hemostatic gelation (Biomimetic Hemostatic Gel):
    • Cresilon’s TraumaGel gel technology rapidly controls bleeding on contact, validated in trauma and penetrating traumatic brain injury studies conducted with the Walter Reed Army Institute of Research.
  3. Engineered wound-sealant mechanics (Advanced Wound Sealants):
    • Brij Medical’s Brij-Seal is engineered for a balance of strength, flexibility and biocompatibility, expanding the company’s incision-management portfolio alongside its BRIJJIT product line.
  4. Polyurethane surgical adhesive chemistry (Polyurethane Surgical Adhesives):
    • Adhesys Medical adapts polyurethane adhesive chemistry for surgical tissue-bonding applications.

Sources 4 · 0 independent · 4 producer sites

Producers' own sites 4

  1. Tissium producer checked 2026-06-24 · link not kept
  2. Adhesys medical producer checked 2026-07-14 · link not kept
  3. Cresilon producer checked 2026-07-07 · link not kept
  4. Brij medical producer checked 2026-07-17 · link not kept